[Seattle, Washington, October 31, 2022] – Remmie, Inc., a medical technology company announced today that they received a Phase I SBIR award from the National Institutes of Health’s National Institute on Deafness and Other Communication Disorders (NIDCD). With Remmie’s proposed Remmie.ai method, the suite of digital at-home connected otoscope will leverage cloud service and API interface for clinicians to not only have a clear view remotely, but also receive assistance, in-person or remotely, in making clinical decisions on ENT conditions, powered by a deep learning AI/ML engine.

The NIDCD conducts and supports research in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language.

According to NIH, Phase I awards provide the opportunity to establish the scientific, technical, and commercial merit and feasibility of the proposed innovation. This $350,000 Phase I SBIR award will fund Remmie.ai: a deep learning diagnosis assistance engine for ENT diseases. 

Current diagnostic tools involving analog otoscope and in-person visits for ENT conditions. “We are excited and honored about NIDCD’s support of our development of Remmie.ai, which in conjunction with Remmie’s connected digital otoscope and API services, has the potential to transform ENT care towards massive access, higher quality, and lower costs for providers, patients, and payers”, said Jane Zhang, PhD/MBA, Remmie’s Co-founder and CEO, Affiliate Assistant Professor of University of Washington Mechanical Engineering, and principal investigator on this project. “We received strong support from the UnitedHealthcare Accelerator, the Techstars, Life Science Washington, and Medtronic Labs, and plan to continue to work with clinicians in the University of Washington and the West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) to test the implementation." 

About the National Institute on Deafness and Other Communication Disorders (NIDCD): The NIDCD supports and conducts research and research training on the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language and provides health information, based upon scientific discovery, to the public.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.

About Remmie: Remmie helps families play a more active role in their health from the convenience of home by bringing connected ENT-examination into their hands to share with a doctor online. Remmie uses technology to target the most common reason Americans go to the doctor's office, ear, nose, throat, and common upper respiratory conditions. The Remmie solution suite include a digital otoscope kit, APIs to link with telehealth and e-health provider platforms, and a pipeline ML/AI diagnosis assistance engine.

For more information about Remmie, visit www.remmiehealth.com, or connect with Remmie on Facebook, Twitter, Instagram, YouTube, or LinkedIn. 

The research reported in this press release is supported by the National Institute on Deafness and Other Communication Disorders (NIDCD) of the National Institutes of Health (NIH) under Award Number 1R43DC020868. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.